optimizing biosimilars for safe and effective management of imids
Published 5 years ago • 349 plays • Length 39:48Download video MP4
Download video MP3
Similar videos
-
53:18
utilization of biosimilars: achieving value-based plan management
-
14:19
regulatory pathway for biosimilars
-
16:47
what is needed and what is the role of biosimilars?
-
18:23
biosimilars for ibd: to start, switch, or stay away?
-
33:34
optimizing the efficacy of immunomodulators and biologics in pediatric ibd
-
16:44
the current landscape of biosimilars in ibd
-
20:47
biosimilars for ibd: start, switch, or stay away?
-
2:47
biosimilars: approval process
-
21:21
beyond reference biologics: biosimilars on the horizon
-
51:06
biosimilars and oncology clinical pathways: perfect together
-
11:40
debate: biosimilar therapies - caution, more studies are needed
-
1:35
biosimilars: safety & efficacy
-
0:51
fast facts about extrapolation for biosimilars - amgen science
-
38:15
biosimilars and biologics
-
57:53
biosimilars: what you need to know
-
14:31
biosimilars and interchangeables - regulatory highlights (27of33) quality – oct. 16-17, 2019
-
3:45
what are biosimilars? how do they work for arthritis?
-
7:07
biosimilar use in the treatment of nsclc
-
20:06
biologics and biosimilars: extrapolation of indications – information for healthcare providers